Intracellular Net Worth
Intracellular Net Worth Breakdown | ITCI |
Intracellular Net Worth Analysis
Intracellular's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Intracellular's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Intracellular's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Intracellular's net worth analysis. One common approach is to calculate Intracellular's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Intracellular's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Intracellular's net worth. This approach calculates the present value of Intracellular's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Intracellular's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Intracellular's net worth. This involves comparing Intracellular's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Intracellular's net worth relative to its peers.
Enterprise Value |
|
To determine if Intracellular is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Intracellular's net worth research are outlined below:
| The company reported the previous year's revenue of 464.37 M. Net Loss for the year was (139.67 M) with profit before overhead, payroll, taxes, and interest of 95.16 M. | |
| Intracellular Th currently holds about 628.74 M in cash with (124.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.64. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Intra-cellular therapies president sells 3.69 million in stock |
Intracellular uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Intracellular Th. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intracellular's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Intracellular's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Intracellular is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intracellular Th backward and forwards among themselves. Intracellular's institutional investor refers to the entity that pools money to purchase Intracellular's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Franklin Resources Inc | 2024-09-30 | 1.8 M | Clearbridge Advisors, Llc | 2024-09-30 | 1.7 M | Geode Capital Management, Llc | 2024-09-30 | 1.7 M | Perceptive Advisors Llc | 2024-09-30 | 1.6 M | Deep Track Capital, Lp | 2024-09-30 | 1.6 M | Suvretta Capital Management, Llc | 2024-06-30 | 1.6 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.4 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.4 M | Holocene Advisors, Lp | 2024-09-30 | 1.4 M | Fmr Inc | 2024-09-30 | 11.1 M | Vanguard Group Inc | 2024-09-30 | 9.6 M |
Follow Intracellular's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.08 B.Market Cap |
|
Project Intracellular's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.26) | (0.28) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.24) | (0.25) |
When accessing Intracellular's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Intracellular's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Intracellular's profitability and make more informed investment decisions.
Evaluate Intracellular's management efficiency
Intracellular Th has return on total asset (ROA) of (0.0745) % which means that it has lost $0.0745 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.099) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.2. The current Return On Capital Employed is estimated to decrease to -0.28. As of now, Intracellular's Non Currrent Assets Other are increasing as compared to previous years. The Intracellular's current Deferred Long Term Asset Charges is estimated to increase to about 635.1 K, while Total Assets are projected to decrease to under 410.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.17 | 5.03 | |
| Tangible Book Value Per Share | 6.17 | 5.03 | |
| Enterprise Value Over EBITDA | (42.41) | (40.29) | |
| Price Book Value Ratio | 11.61 | 7.67 | |
| Enterprise Value Multiple | (42.41) | (40.29) | |
| Price Fair Value | 11.61 | 7.67 | |
| Enterprise Value | 6.7 B | 7.1 B |
Intracellular showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 13.2114 | Revenue 613.7 M | Quarterly Revenue Growth 0.39 | Revenue Per Share 6.096 | Return On Equity (0.1) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intracellular insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intracellular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intracellular insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Intracellular Corporate Filings
F4 | 14th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 10th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Intracellular Earnings per Share Projection vs Actual
Intracellular Corporate Management
| CPA CPA | CFO, Fin | Profile | |
| Suresh MD | Executive Officer | Profile | |
| Karen Esq | Senior Officer | Profile | |
| Willie MD | Senior Development | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.87) | Revenue Per Share 6.096 | Quarterly Revenue Growth 0.39 | Return On Assets (0.07) | Return On Equity (0.1) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.